PMGC Holdings (ELAB) Total Non-Current Liabilities (2023 - 2026)
PMGC Holdings (ELAB) posted Total Non-Current Liabilities of $62123.0 for Q1 2026, up 100.58% sequentially from $30972.0 in Q4 2025.
PMGC Holdings (ELAB) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
PMGC Holdings has reported Total Non-Current Liabilities for 4 years, with the latest figure at $62123.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $62123.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62123.0 (changed N/A YoY) and the FY2025 annual result came in at $30972.0, down 94.21% from the prior year.
- Total Non-Current Liabilities rose to $62123.0 in Q1 2026 per ELAB's latest filing, from $30972.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $985671.0 in Q3 2025 and troughed at $30972.0 in Q4 2025.
- A 4-year average of $335744.4 and a median of $65489.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 716.12% in 2024, then sank 94.21% in 2025.
- Over 4 years, Total Non-Current Liabilities stood at $65489.0 in 2023, then surged by 716.12% to $534467.0 in 2024, then tumbled by 94.21% to $30972.0 in 2025, then soared by 100.58% to $62123.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $62123.0, $30972.0, and $985671.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 9.32 Bn |
| 10 | PMGC Holdings | 31.99 Mn | 13.20 Mn | 385,691.00 | 4.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,123.00 |
| Dec 31, 2025 | 30,972.00 |
| Sep 30, 2025 | 985,671.00 |
| Dec 31, 2024 | 534,467.00 |
| Dec 31, 2023 | 65,489.00 |